

FOI 3287

8th September 2025**FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST**

Q1. How many patients have been treated (for any condition) in the last 4 months with:

Response:

Current patients as of 15-08-25

- Benralizumab - 0
- Dupilumab – 132
- Omalizumab - 40
- Reslizumab - 0
- Mepolizumab - 0
- Tezepelumab - 0

Q2. Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups:

Response:

- Age 6-11 - <5
- Age 12-17 - 5
- Age 18 and above – 166

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Q3. How many patients have been treated in the last 4 months by the Respiratory Medicine department ONLY with:

Response:

- **Dupilumab**
- **Omalizumab**

No patients within Respiratory were treated with the medications listed above in the last 4 months. This is a tertiary level service and all patients deemed potentially appropriate are referred to Belfast Health & Social Care Trust for consideration.

Email: Foi.Team@Southerntrust.hscni.net